<DOC>
	<DOCNO>NCT01134692</DOCNO>
	<brief_summary>Chronic peripheral splanchnic vasodilatation hallmark hemodynamic abnormality cirrhosis contribute pathogenesis portal hypertension . Alterations intestinal motility bacterial overgrowth gut may predispose development bacteraemia endotoxaemia cirrhotic patient play role hyperdynamic circulatory syndrome cirrhosis . Probiotic therapy aim change make-up indigenous microflora administer specific strain non-pathogenic potentially beneficial microflora . In study , investigator hypothesize modification composition endogenous digestive microflora oral bacteriotherapy high potency probiotic preparation could safe way regulate portal pressure . As relative paucity effective pharmacological treatment portal hypertension , novel innovative therapy might provide important alternative adjunct therapy beta blocker clinical management patient portal hypertension . Aims objectives To study patient cirrhosis large varix whether probiotic and/or norfloxacin give 2 month : 1. achieve reduction HVPG 2. alter endotoxin cytokine level , improve systemic inflammatory response 3. well tolerate . Inclusion criterion : Consecutive patient cirrhosis portal hypertension fulfill follow criterion : 1 . Diagnosed case cirrhosis ( clinical , biochemical radiological criterion without liver biopsy ) 2 . No history upper GI bleeding past 3 . Endoscopically documented large esophageal varix Exclusion criterion 1. history gastrointestinal bleeding 2. patient receive beta blocker portal hypertension past 6 week . 3. hepatic encephalopathy 4. ongoing bacterial infection , 5 . Spontaneous bacterial peritonitis 6. active alcoholism illicit drug abuse 7. alcoholic hepatitis 8 . Treatment antibiotic precede 2 week . 9. presence hepatocellular carcinoma , 10. portal vein thrombosis 11. serum creatinine &gt; 1.5 mg/dL , 12. treatment vasoactive drug past 6 week , 13. history arterial hypertension , congestive heart failure arterial occlusive disease , 14 . Refusal participate . 15 . Active smoker . Study plan : Ethical approval obtain prior study initiation . Patients present Department Gastroenterology , GB Pant Hospital recruit study . Patients evaluate regard eligibility study . After find eligible study , patient agrees participate study , sign informed consent obtain . Baseline HVPG measure patient randomize 3 group : . 1 . Group 1 : Beta blocker + placebo 2 . Group 2 : Beta blocker + Norfloxacin ( 400mg BD ) 3 . Group 3 : Beta blocker + probiotic . ( one sachet VSL # 3 BD ) 30 patient enrol group . The treatment continue 2 month . The study design randomize double-blinded placebo control trial . Once patient enrol , undergo baseline investigation . Blood drawn peripheral hepatic vein send routine parameter , pro-inflammatory cytokine ( IL-1b , IL-6 , IL-10 , TNF-α , endotoxins , NO2 NO3 level , PRA , BNP ) . Samples store -70 ºC . Baseline vitals record . Patients call end 1 month assessment compliance end study ( 2 month ) repeat HVPG parameter time enrollment End Points : 1 . Primary . Change HVPG level compare baseline , define responder ( ≥20 % reduction HVPG ≤ 12 mm Hg ) . 2 . Secondary 1 . Change digestive flora 2 . Reduction serum hepatic endotoxin cytokine level 3 . Assessment improvement renal parameter Systemic inflammatory response syndrome 4 . Improvement marker oxidative injury 5 . Adverse effect</brief_summary>
	<brief_title>Probiotics Portal Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Norfloxacin</mesh_term>
	<criteria>Consecutive patient cirrhosis portal hypertension fulfill follow criterion : 1 . Diagnosed case cirrhosis ( clinical , biochemical radiological criterion without liver biopsy ) 2 . No history upper GI bleeding past 3 . Endoscopically documented large esophageal varix 1. history gastrointestinal bleeding 2. patient receive beta blocker portal hypertension past 6 week . 3. hepatic encephalopathy 4. ongoing bacterial infection , 5 . Spontaneous bacterial peritonitis 6. active alcoholism illicit drug abuse 7. alcoholic hepatitis 8 . Treatment antibiotic precede 2 week . 9. presence hepatocellular carcinoma , 10. portal vein thrombosis 11. serum creatinine &gt; 1.5 mg/dL , 12. treatment vasoactive drug past 6 week , 13. history arterial hypertension , congestive heart failure arterial occlusive disease , 14 . Refusal participate . 15 . Active smoker .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Patients cirrhosis large esophageal varix No history upper GI bleeding past</keyword>
</DOC>